Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Bijblijven
Gepubliceerd in: Bijblijven 7/2015

03-09-2015

Nieuwe vaccins

Auteurs: Dr. Annick Hens, Dr. Valerie Asselman, Dr. Ilse De Coster, Prof. Pierre Van Damme

Gepubliceerd in: Bijblijven | Uitgave 7/2015

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

De wetenschappelijke kennis over vaccins evolueert in hoog tempo, de epidemiologie van infectieziekten verandert voortdurend en nieuwe vaccins verschijnen op de markt. Voor een aantal belangrijke tropenziekten schetst deze bijdrage de bestaande vaccins met hun beperkingen en geeft een beeld van de vaccins die in ontwikkeling zijn.
De cholera- en tyfusvaccins die momenteel op de markt zijn, zijn zeker voor verbetering vatbaar. Toenemende dreiging van andere infectieziekten, zoals ebola en de arbovirussen chikungunya en dengue, toont het belang om bij te blijven met de laatste ontwikkelingen van nieuwe vaccins.
vorige artikel Ouderen op reis
Literatuur
1.
Cleton N, Koopmans M, Reuskens C. Medisch belangrijke arbovirusinfecties voor internationale reizigers. Tijdschr Infectieziekten 2013;8(6):185–96.
2.
Lin L, Thomas S. Current dengue vaccine status. Curr Trop Med Rep. 2014;1:6–12.CrossRef
3.
4.
Tomasello D, Schlagenhauf P. Chikungunya and dengue autochthonous cases in Europe, 2007–2012. Travel Med Infect Dis. 2013;11:274–84.CrossRefPubMed
5.
Wressnigg N, Van der Velden M, Portsmouth D, Draxler W, O’rourke M, Richmond P, et al. An inactivated ross river virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial. Clin Vaccine Immunol. 2015;22(3):267–73.PubMedCentralCrossRefPubMed
6.
Visser L, Groen J. Gewrichtspijn en exantheem uit Australië, veroorzaakt door Ross-river-virus. Ned Tijdschr Geneesk. 2003;147(6):254–7.
7.
Schleenvoigt B, Baier M, Hagel S, Forstner C, Kötsche R, Pletz M. Ross river virus infection in a Thuringian traveler returning from south-east Australia. Infection 2015;43(2):229–30.CrossRefPubMed
8.
Jones A, Lowry K, Aaskov J, Holmes E, Kitchen A. Molecular evolutionary dynamics of ross river virus and implications for vaccine efficacy. J Gen Virol. 2010;91:182–8.CrossRefPubMed
9.
Aichinger G, Ehrlich H, Aaskov J, Fritsch S, Thomasser C, Draxler W, et al. Safety and immunogenicity of an inactivated whole virus vero cell-derived ross river virus vaccine: a randomized trial. Vaccine 2011;29:9376–84.CrossRefPubMed
10.
Weaver S, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015;372(13):1231–9.CrossRefPubMed
11.
Edelman R, Tacket C, Wasserman S, Bodison S, Perry J, Mangiafico J. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 2000;62(6):681–5.PubMed
12.
13.
Chang L, Dowd K, Mendoza F, Sounders J, Sitar S, Plummer S, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014;384:2046–52.CrossRefPubMed
14.
15.
Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak R, Thomas S, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomized, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015;15(5):519–27.CrossRefPubMed
16.
17.
Thiry G, Hombach J, Constenia D, Carvalho A, Durbin A. New chapter unfolding in the fight against dengue with an unwritten ending. Trans R Soc Trop Med Hyg. 2014;108:597–8.CrossRefPubMed
18.
Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh TC, Chua M. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 2014;384:1358–65.CrossRefPubMed
19.
Villar L, Dayan G, Arredondo-Garcia J, Rivera D, Cunha R, Deseda C. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372:113–23.CrossRefPubMed
20.
21.
22.
Cholera vaccines. WHO position paper. Wkly Epidemiol Record 2010;85:117–28.
23.
24.
Pastor M, Pedraz JL, Esquisabel A. The state-of-the-art of approved and under-development cholera vaccines. Vaccine 2013;31:4069–78.CrossRefPubMed
25.
26.
27.
Riedmann EM. The latest on PaxVax’ and Gotovax AB’s cholera vaccine candidates. Hum Vaccin Immunother. 2014;10(8):2142.
28.
O’Ryan M, Vidal R, Del Canto F, Salazar JC, Montero D. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: part I: overview, vaccines for enteric viruses and Vibrio cholerae. Hum Vaccin Immunother. 2015;11(3):584–600. (epub).CrossRef
29.
Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun. 2002;70:1965–70.PubMedCentralCrossRefPubMed
30.
Chen WH, Garza J, Choquette M, Hawkins J, Hoeper A, Bernstein DI, et al. Safety and immunogenicity of escalating dosages of a single oral administration of Peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae. Clin Vaccine Immunol. 2015;22(1):129–35.PubMedCentralCrossRefPubMed
31.
Kanungo S, Sen B, Ramamurthy T, Sur D, Manna B, Pazhani GP, et al. Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India. PLoS One 2014;9(7):e99381.PubMedCentralCrossRefPubMed
32.
Clemens JD, Shin S, Sah BK, Sack DA. Cholera vaccins. In: Plotkin SA, Orenstein WA, Offit PA, redactie. Vaccines. 6th ed. Philadelphia: Elsevier; 2013.
33.
Martin S, Lopez AL, Bellos A, Deen J, Ali M, Alberti K, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ. 2014;92(12):881–93.PubMedCentralCrossRefPubMed
34.
Levine M. Typhoid fever vaccines. In: Plotkin SA, Orenstein WA, Offit PA, redactie. Vaccines. 6th ed. Philadelphia:Elsevier; 2013.
35.
Waddington C, Darton T, Pollard A. The challenge of enteric fever. J Infect. 2014;68:38–50.CrossRef
36.
37.
MacLennan C, Martin L, Micoli F. Vaccines against invasive Salmonella disease. Hum Vaccin Immunother. 2014;10:1478–93.CrossRefPubMed
38.
Marathe SA, Lahiri A, Negi VD, Chakravorthy D. Typhoid fever and vaccine development: a partially answered question. Indian J Med Res. 2012;135(2):161–9.PubMedCentralPubMed
39.
Thiem DT, Lin FY, Canh DG, Anh DD, Chu C, Hunt S, et al. The Vi conjugate vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol. 2011;18(5):730–5.PubMedCentralCrossRefPubMed
40.
Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344(17):1263–9.CrossRefPubMed
41.
Van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, et al. Safety, immunogenicity and dose ranging of a new Vi- CRM 197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One 2011;6(9):e25398.PubMedCentralCrossRefPubMed
42.
Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, et al. Immunogenicity and safety of the Vi-CRM 197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from 2 randomised, observer-blind, age de-escalation, phase-2 trials. Lancet 2014;14(2):119–29.CrossRefPubMed
43.
Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, et al. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 × 1010 colony-forming units. Vaccine 2010;28:3602–8.CrossRefPubMed
44.
Tinh Hien T, Thi Dung N, Thanh Truong N, Van Thanh N, Nguyen Bich Chan T, Van Minh Hoang N, et al. A randomized trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One 2010;5(7):e11778.CrossRef
45.
Tacket CO. Levine M.CVD908,CVD908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. CID. 2007;45(Suppl 1):20–3.CrossRef
46.
47.
48.
Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2001;29:304–13.CrossRef
49.
Martin J, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA Vaccine for ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13(11):1267–77.PubMedCentralCrossRefPubMed
50.
Kanapathipillai R, Henao Restrepo AM, Fast P, Wood D, Dye C, Kieny MP, Moorthy V. Ebola vaccine – an urgent international priority. N Engl J Med. 2014;371(24):2249–51.CrossRefPubMed
51.
Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 Trials of rVSV Ebola vaccine in Africa and Europe – preliminary report. N Engl J Med. 2015. doi:10.1056/NEJMoa502924.
52.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Muñoz P, et al. A recombinant vesicular stomatitis virus Ebola vaccine – preliminary report. N Engl J Med. 2015. doi:10.1056/NEJMoa414216.
53.
Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, et al. Chimpanzee Adenovirus vector Ebola vaccine – preliminary report. N Engl J Med. 2014. doi:10.1056/NEJMoa1410863.
54.
55.
56.
Metagegevens
Titel
Nieuwe vaccins
Auteurs
Dr. Annick Hens
Dr. Valerie Asselman
Dr. Ilse De Coster
Prof. Pierre Van Damme
Publicatiedatum
03-09-2015
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Bijblijven / Uitgave 7/2015
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI
https://doi.org/10.1007/s12414-015-0061-x

Andere artikelen Uitgave 7/2015

Bijblijven 7/2015 Naar de uitgave

OriginalPaper

Ouderen op reis

OriginalPaper

With a little help of my friend: computerhulp bij koorts na terugkeer uit de tropen

Editorial

Redactioneel ten geleide

OriginalPaper

Maag-darmproblemen bij importziekten

OriginalPaper

SIKKELCELZIEKTE

OriginalPaper

Andere interessante importziekten